Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loracarbef Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | SLC15A2 | Q16348 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loracarbef Anhydrous SCHEMBL2223190 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL537031 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL1229813 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL9505437 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL8932366 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL7592549 | 1.00 | KDM4E (0.67) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL7588189 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL13457172 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL17530291 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10CYP2C9MAPT | |
| Loracarbef Anhydrous SCHEMBL10692457 | 0.99 | KDM4E (0.66) | KDM4EALDH1A1HSD17B10CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18771 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146115-A1 | POLYETHYLENE COMPOSITION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-05-28 | — | — | US | claimed |
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-117321133-B | Modified low-density polyethylene resin and preparation method thereof | 陶氏环球技术有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4735487-A1 | BLOW MOLDED ARTICLES | Dow Global Technologies LLC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4702064-A1 | POLYMERIZATION PROCESS, HDPE POLYETHYLENE COMPOSITION AND ROTOMOLDED ARTICLE | Nova Chemicals (International) S.A. (CH) | 2026-03-04 | — | — | EP | claimed |
| EP-4695086-A1 | MULTILAYER FILM STRUCTURES AND PACKAGES COMPRISING THE SAME | Nova Chemicals (International) S.A. (CH) | 2026-02-18 | — | — | EP | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4683954-A1 | REACTOR BLEND ETHYLENE POLYMER COMPOSITIONS AND FILMS | Nova Chemicals (International) S.A. (CH) | 2026-01-28 | — | — | EP | claimed |
| WO-1996024684-A1 | POTENTIATORS OF ANTIBACTERIAL AGENTS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1996-08-15 | — | — | WO | claimed |
| EP-0680322-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING CLAVULANIC ACID ALONE OR IN COMBINATION WITH OTHER BETA-LACTAM ANTIBIOTICS | SMITHKLINE BEECHAM PLC (GB) | 1995-11-08 | — | — | EP | claimed |
| US-5409917-A | Topical treatment of acne with cephalosporins | Towsend, Marvin S. (US) | 1995-04-25 | — | — | US | claimed |
| EP-0637587-A1 | Bicyclic beta-lactam/paraben complexes | ELI LILLY AND COMPANY (US) | 1995-02-08 | — | — | EP | claimed |
| EP-0629625-A1 | Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof | ELI LILLY AND COMPANY (US) | 1994-12-21 | — | — | EP | claimed |
| EP-0627431-A1 | Process for preparing crystalline loracarbef monohydrate | ELI LILLY AND COMPANY (US) | 1994-12-07 | — | — | EP | claimed |
| US-5352782-A | By steaming | ELI LILLY AND COMPANY (US) | 1994-10-04 | — | — | US | claimed |
| WO-1994016696-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING CLAVULANIC ACID ALONE OR IN COMBINATION WITH OTHER BETA-LACTAM ANTIBIOTICS | SMITHKLINE BEECHAM PLC (GB) | 1994-08-04 | — | — | WO | claimed |
| EP-0280571-B1 | SUSTAINED RELEASE MATRIX FORMULATIONS | ELI LILLY AND COMPANY (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0549264-A1 | Purified para-nitrobenzyl esterase from bacillus | OKLAHOMA STATE UNIVERSITY (US) | 1993-06-30 | — | — | EP | claimed |